• Thea K Fischer, Dang Duc Anh, Lynn Antil, N D L Cat, Paul E Kilgore, Vu D Thiem, Rick Rheingans, Le H Tho, Roger I Glass, and Joseph S Bresee.
• Division of Viral and Rickettsial Diseases and Epidemiology Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
• J. Infect. Dis. 2005 Nov 15; 192 (10): 1720-6.

BackgroundRotavirus disease causes a significant health and economic burden worldwide. Several rotavirus vaccines may soon be available for use. A country's decision to introduce these vaccines will depend on its rotavirus disease burden, on the cost of the vaccine, and on the results of an economic assessment of the cost and effectiveness of a rotavirus vaccination program.MethodsData on medical and nonmedical direct costs and indirect costs were established in Khanh Hoa Province, Vietnam, and extrapolated to national estimates on the basis of the birth cohort in 2004. The main outcome measures were economic burden and cost-effectiveness ratio (United States dollars per disability-adjusted life-year averted and dollars per life saved) of vaccination.ResultsThe disease burden is equivalent to an economic burden of an estimated 3.1 million US dollars in medical direct costs, 685,000 US dollars in nonmedical direct costs, and 1.5 million US dollars in indirect costs. From a societal perspective, treatment of rotavirus disease costs an estimated 5.3 million US dollars per year. From the health care system perspective, universal vaccination of infants at a cost of < or = 7.26 US dollars/vaccine dose would be a cost-effective public health intervention, according to the World Bank cost-effectiveness standard for low-income countries (140 US dollars/disability-adjusted life-year).ConclusionsVaccination can effectively reduce the disease burden and health care costs of rotavirus-specific diarrhea in Vietnam.

25 keywords...

hide…